Diplomat Pharmacy (NYSE:DPLO) will announce its earnings results after the market closes on Monday, February 26th. Analysts expect the company to announce earnings of $0.16 per share for the quarter.
Diplomat Pharmacy (NYSE:DPLO) opened at $24.10 on Monday. Diplomat Pharmacy has a fifty-two week low of $13.39 and a fifty-two week high of $27.78. The stock has a market capitalization of $1,660.00, a price-to-earnings ratio of 200.83 and a beta of 1.05. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82.
DPLO has been the topic of several research analyst reports. Robert W. Baird downgraded Diplomat Pharmacy from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $24.00 to $18.00 in a research note on Thursday, November 16th. Mizuho set a $25.00 target price on Diplomat Pharmacy and gave the stock a “hold” rating in a research note on Wednesday, January 24th. BidaskClub downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Deutsche Bank initiated coverage on Diplomat Pharmacy in a research note on Monday, December 4th. They set a “buy” rating and a $22.00 target price on the stock. Finally, Needham & Company LLC boosted their target price on Diplomat Pharmacy from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, January 8th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $23.95.
TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/19/diplomat-pharmacy-dplo-set-to-announce-earnings-on-monday-2.html.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.